Thomas D. Coates
Indiana University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Thomas D. Coates.
The New England Journal of Medicine | 1982
Laurence A. Boxer; Thomas D. Coates; Richard A. Haak; J. Baruch Wolach; Sylvia Hoffstein; Robert L. Baehner
EIGHT years ago Strauss et al. reported unique structural abnormalities in the granulocytes of a boy who had had recurrent bacterial infections since birth.1 The nuclei were bilobed, and in ultrast...
Cancer | 1980
John R. Priest; Norma K.C. Ramsay; Richard E. Latchaw; Lawrence A. Lockman; Duane K. Hasegawa; Thomas D. Coates; Peter F. Coccia; J. Roger Edson; Mark E. Nesbit; William Krivit
Sudden cerebrovascular insults occurred during or immediately following remission induction therapy in 4 children with acute lymphoblastic leukemia. In 3, cerebral infarction was due to thrombosis. In the fourth, an intracerebral hematoma developed representing either frank hemorrhaging or a hemorrhagic infarction. None of the patients had central nervous system leukemia or extreme leukocytosis at the time of diagnosis. Symptoms were obtundation, hemiparesis, seizures, and headache. The induction chemotherapy included L‐asparaginase which causes deficiencies of antithrombin, plasminogen, fibrinogen, and factors IX and XI. These hemostatic abnormalities may explain the thromboses and bleeding observed in these children.
Cancer | 1983
Karyl A. Rickard; Catherine M. Detamore; Thomas D. Coates; Jay L. Grosfeld; Robert M. Weetman; Nancy Matchett White; Arthur J. Provisor; Laurence A. Boxer; Emily Loghmani; Tjien O. Oei; Pao‐lo ‐l Yu; Robert L. Baehner
The effect of the state of nutrition of 18 children with Stage IV neuroblastoma at diagnosis and during initial therapy, was evaluated with respect to treatment delays, drug dosage alterations, tumor response, days to first event (relapse or death), and survival. All patients received similar therapy (CCSG protocol CCG 371). Based on nutrition staging at diagnosis, nine were classified as malnourished; four were randomized to receive total parenteral nutrition (TPN) and four peripheral parenteral nutrition plus enteral nutrition for 28 days (through 2 chemotherapy courses), and one died before randomization. Nine were nourished at diagnosis; seven received a comprehensive enteral nutrition program and two received TPN. By life‐table analysis, the duration of remission was significantly greater in the nourished than the malnourished (P < 0.01) and a trend towards improved survival was evident at one year (P = 0.08). The median length of survival for children nourished at diagnosis was approximately 12 months, whereas those malnourished had a median survival of only 5 months. Nine children remained nourished or were becoming renourished during the first 21 days of therapy, and one of these had treatment delays and decreased drug dosages. Seven were becoming malnourished or remained malnourished during this period and six had treatment delays (P < 0.01). These data support the idea that nutrition staging at diagnosis and during initial treatment should be an integral part of protocol design and initial evaluation of children with Stage IV neuroblastoma.
Cancer | 1985
Karyl A. Rickard; Emily Loghmani; Jay L. Grosfeld; Catherine Detamore Lingard; Nancy Matchett White; Beth Bartlett Foland; Barbara L. Jaeger; Thomas D. Coates; Pao-Lo Yu; Robert M. Weetman; Arthur J. Provisor; Tjien O. Oei; Robert L. Baehner
The effectiveness of enteral and parenteral nutrition regimens in preventing or reversing protein–energy malnutrition (PEM) and in preventing treatment delays was evaluated in 32 children receiving treatment for newly diagnosed Stage III (3 patients) and IV (29 patients) neuroblastoma. Ten of 18 malnourished patients were randomized to central parenteral nutrition (CPN) and 8 to peripheral parenteral nutrition (PPN) plus enteral nutrition for 4 weeks and then received enteral nutrition (EN: intense nutrition counselling, oral foods and supplements) for weeks 5 through 10. Ten of 14 nourished patients received EN and 4 CPN for 4 weeks and EN thereafter. Dietary, anthropometric and biochemical measurements were determined for weeks 0, 1, 2, 3, 4, 7, and 10 for 24 patients who completed the protocols. In malnourished patients, both CPN (seven patients) and PPN (seven patients) were effective in reversing PEM in the first 4 weeks; thereafter, EN effectively maintained nutritional gains in both groups. In nourished patients, EN (seven patients) was not as effective as CPN (three patients) in preventing PEM during the first 4 weeks; afterwards, EN maintained gains in the CPN group but did not promote needed increases in weight nor fat reserves in the EN group. Patients supported by parenteral nutrition (PN, weeks 1–4) had fewer treatment delays (2/17, 12%) than EN patients (4/7, 57%, P <0.05). These data indicate that PN reverses or prevents PEM and prevents treatment delays during the first 4 weeks of intense oncologic treatment and provides nutritional benefits which can be maintained with EN thereafter.
Cancer | 1986
Karyl A. Rickard; Thomas D. Coates; Jay L. Grosfeld; Robert M. Weetman; Robert L. Baehner
The Journal of Pediatrics | 1977
Richard L. Schreiner; Thomas D. Coates; Penelope G. Shackelford
Cancer | 1989
Karyl A. Rickard; Barbara Jaeger Godshall; Emily Loghmani; Thomas D. Coates; Jay L. Grosfeld; Robert M. Weetman; Catherine Detamore Lingard; Beth Bartlett Foland; Po-Lo Yu; Warren A. McGuire; Arthur J. Provisor; Tjien O. Oei; Robert L. Baehner
Cancer | 1989
Karyl A. Rickard; Mary Corcoran Becker; Emily Loghmani; Jay L. Grosfeld; Barbara Jaeger Godshall; Robert M. Weetman; Thomas D. Coates; Catherine Detamore Lingard; Nancy Matchett White; Beth Bartlett Foland; P.L. Yu; Warren A. McGuire; Arthur J. Provisor; T-Jien O. Oei; Robert L. Baehner
Journal of Laboratory and Clinical Medicine | 1982
Wolach B; DeBoard Je; Thomas D. Coates; Robert L. Baehner; Laurence A. Boxer
Journal of Cell Biology | 1982
Thomas D. Coates; L. K. Han; L. A. Boxer; Robert L. Baehner